Skip to content
MARKETS / NASDAQ / ALVO
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Alvotech ALVO

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$586.3M
▲ 19.7% YoY
$27.9M
$-114.7M
In brief

What this company does

Alvotech develops and manufactures biosimilar medicines for patients worldwide as a vertically integrated biotechnology company focused solely on that business. It currently has five approved products and an additional thirty product candidates in its pipeline, targeting autoimmune, eye, respiratory and hematological disease, as well as cancer. Its corporate headquarters, main manufacturing site and a large part of its R&D division are located in Reykjavik, Iceland, in a purpose-built facility of approximately 280,000 square feet that uses single-use technology to manufacture drug substance and drug product. It licenses its biosimilars intellectual property to commercialization partners in exchange for development and commercialization milestone payments and royalties on sales.

Written from the business description in Alvotech's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 586.3M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 586.3 · Net income 27.9
200M400M-200M-400M202020212022202320242025
Compound annual growth
+91.9%
+54.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +54.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 13.3% · Net 4.8%
-200%-400%-600%202020212022202320242025
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -114.7
-200M202020212022202320242025

Total assetsUSD 1.5B
CashUSD 172.4M
Gross debtUSD 1.3B
Net debtUSD 1.1B
Current ratio1.89×

Not available: we don't have the shareholders' equity figure for this period.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.60.50.10.10.00.1
Operating income $B0.10.1−0.4−0.3−0.2−0.1
EBITDA $B0.10.1−0.3−0.3−0.2−0.1
Income tax $B0.10.0−0.1−0.0−0.0−0.1
Net income $B0.0−0.2−0.6−0.5−0.1−0.2
Free cash flow $B−0.1−0.3−0.3−0.4−0.2−0.1
EPS, diluted $0.10−0.87−2.43−2.60−0.92−1.82
Dividend / sh $······
Payout %······
ROE %······
Shares out B0.310.300.270.250.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 22 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 68 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code N4
Fiscal year endsDecember 31
Data on record since2020

Share this section

Download image